

## PACKAGE INSERT

### 1. PRODUCT NAME

BELKYRA


### 2. NAME AND STRENGTH OF ACTIVE INGREDIENT (S)

BELKYRA (deoxycholic acid) Injection

Each mL of the solution contains 10 mg of deoxycholic acid (10 mg/mL)

### 3. PRODUCT DESCRIPTION

BELKYRA (deoxycholic acid) injection, 10 mg/mL is a clear colorless, sterile solution for subcutaneous use. It contains a cytolytic agent, deoxycholic acid, as the active ingredient. The chemical name of deoxycholic acid is 3 $\alpha$ ,12 $\alpha$ -dihydroxy-5 $\beta$ -cholan-24-oic acid, and its molecular formula is C<sub>24</sub>H<sub>40</sub>O<sub>4</sub>, and its molecular weight is 392.57 g/mol. The chemical structure of deoxycholic acid is:



Each 2 mL vial of BELKYRA (deoxycholic acid) injection contains 20 mg chemically synthesized (nonanimal-derived) deoxycholic acid as the active ingredient and the following inactive ingredients: benzyl alcohol (18 mg), dibasic sodium phosphate (2.84 mg), sodium chloride (8.76 mg), sodium hydroxide (2.86 mg) in water for injection, USP. Hydrochloric acid and additional sodium hydroxide are added as necessary to adjust the formulation to pH 8.3. Each vial is for single patient use.

### 4. PHARMACODYNAMIC/ PHARMACOKINETICS

#### 4.1 Mechanism of Action

BELKYRA is a cytolytic drug, which when injected into tissue physically destroys the cell membrane causing lysis.

## 4.2 Pharmacodynamics

### *Cardiac Electrophysiology*

At therapeutic doses, BELKYRA does not prolong the QTc interval.

## 4.3 Pharmacokinetics

Endogenous deoxycholic acid plasma levels are highly variable within and between individuals; most of this natural bile component is sequestered in the enterohepatic circulation loop.

### *Absorption and Distribution*

Deoxycholic acid from BELKYRA is rapidly absorbed following subcutaneous injection. After dosing with the maximum recommended single treatment dose with BELKYRA (100 mg), maximum plasma concentrations (mean  $C_{max}$ ) were observed with a median  $T_{max}$  of 18 minutes after injection. The mean ( $\pm$ SD)  $C_{max}$  value was  $1024 \pm 304$  ng/mL and was 3.2-fold higher than average  $C_{max}$  values observed during a 24-hour baseline endogenous period in the absence of BELKYRA. After maximum recommended single treatment dose (100 mg), mean ( $\pm$ SD) deoxycholic acid exposure ( $AUC_{0-24}$ ) was  $7896 \pm 2269$  ng.hr/mL and was 1.6-fold higher over endogenous exposure. Post-treatment deoxycholic acid plasma levels returned to the endogenous range within 24 hours. No accumulation is expected with the proposed treatment frequency.

Deoxycholic acid is extensively bound to proteins in plasma (98%).

### *Metabolism and Excretion*

Endogenous deoxycholic acid is a product of cholesterol metabolism and is excreted intact in feces. Deoxycholic acid is not metabolized to any significant extent under normal conditions. Deoxycholic acid from BELKYRA joins the endogenous bile acid pool in the enterohepatic circulation and is excreted along with the endogenous deoxycholic acid.

### *Specific Populations*

#### *Hepatic Impairment*

BELKYRA has not been studied in subjects with hepatic impairment. Considering the intermittent dose frequency, the small dose administered that represents approximately 3% of the total bile acid pool, and the highly variable endogenous deoxycholic acid levels, the pharmacokinetics of deoxycholic acid following BELKYRA injection is unlikely to be influenced by hepatic impairment.

#### *Pharmacokinetic Effects of Gender*

Deoxycholic acid pharmacokinetics were not influenced by gender.

#### **4.4 Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of BELKYRA.

Deoxycholic acid was negative in a battery of in vitro (Ames test and chromosomal aberration assay in human lymphocytes) and in vivo (rat erythrocyte micronucleus assay) genetic toxicology assays.

No effects on fertility were observed in male and female rats administered deoxycholic acid at subcutaneous doses up to 50 mg/kg (5 times the MRHD based on a mg/m<sup>2</sup> comparison) once weekly prior to and during the mating period and through gestation day 7 in female rats.

#### **4.5 Clinical studies**

Two randomized, multi-center, double-blind, placebo-controlled trials of identical design were conducted to evaluate BELKYRA for use in improvement in the appearance of convexity or fullness associated with submental fat. The trials enrolled healthy adults (ages 19 to 65, BMI  $\leq$  40 kg/m<sup>2</sup>) with moderate or severe convexity or fullness associated with submental fat (i.e., grade 2 or 3 on 5-point grading scales, where 0 = none and 4 = extreme), as judged by both clinician and subject ratings. Subjects received up to 6 treatments with BELKYRA (N=514, combined trials) or placebo (N=508, combined trials) at no less than 1 month intervals. Use of ice/cold packs, topical and/or injectable local anesthesia was allowed during the clinical trials. Injection volume was 0.2 mL per injection site, spaced 1 cm apart into the submental fat tissue, which is also expressed in dose per area as 2 mg/cm<sup>2</sup>. For each treatment session a maximum of 100 mg (10 mL) was permitted over the entire treatment area. Subjects were administered an average of 6.4 mL at the first treatment session, and subjects who received all six treatments were administered an average of 4.4 mL at the sixth treatment session. Fifty-nine percent of subjects received all six treatments.

In these trials, the mean age was 49 years and the mean BMI was 29 kg/m<sup>2</sup>. Most of the subjects were women (85%) and Caucasian (87%). At baseline, 51% of the subjects had a clinician-rated submental fat severity rating of moderate and 49% had a severe submental fat rating.

The co-primary efficacy assessments were based on at least 2-grade and at least 1-grade improvements in submental convexity or fullness on the composite of clinician-reported and patient-reported ratings of submental fat 12 weeks after final treatment. Additionally, changes in submental fat volume were evaluated in a subset of subjects (N=449, combined trials) using magnetic resonance imaging (MRI). Visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were also evaluated using a 6-question survey, with each question rated from 0 (not at all) to 10 (extremely/very much).

Reductions in submental fat volume were observed more frequently in the BELKYRA group compared to the placebo group as measured by the composite clinician and patient ratings (Table 1). The composite response rates by visit are presented in Figure 1.

**Table 1. ≥ 2-Grade and ≥ 1-Grade Composite Clinician and Patient Response 12 Weeks After Final Treatment**


Endpoint	Trial 1		Trial 2	
	BELKYRA (N=256)	Placebo (N=250)	BELKYRA (N=258)	Placebo (N=258)
2-Grade Composite Response <sup>a</sup>	13.4%	<0.1%	18.6%	3.0%
1-Grade Composite Response <sup>b</sup>	70.0%	18.6%	66.5%	22.2%

<sup>a</sup> At least 2 grade reduction on both the clinician-reported and patient-reported ratings of submental fat


<sup>b</sup> At least 1 grade reduction on both the clinician-reported and patient-reported ratings of submental fat

**Figure 1.  $\geq 2$ -Grade and  $\geq 1$ -Grade Composite Clinician and Patient Response**

At Least 2-Grade Reduction Composite Response



At Least 1-Grade Reduction Composite Response




Note: Subjects were followed up 4, 12 and 24 weeks after the last treatment. Forty-one percent of subjects received fewer than 6 treatments and entered the post-treatment period earlier than Week 24.

A greater proportion of BELKYRA-treated subjects had at least a 10% reduction in submental fat volume as compared to placebo-treated subjects when evaluated by MRI (43% vs 5%, respectively).

The overall patient-reported satisfaction and self-perceived visual attributes showed greater improvement in the BELKYRA group than in the placebo group, presented in Figure 2.

**Figure 2 Mean SMF Impact Change 12 Weeks after Last Treatment\***



Despite the majority of subjects having reductions in SMF volumes, > 90.0% of subjects had no change or an improvement in skin laxity scores at Week 32 (12 weeks after last treatment) compared with baseline.

The long-term safety and maintenance of efficacy responders has been assessed following treatment with BELKYRA. A subset of the initial BELKYRA-treated responders continued in these follow-up studies, where maintenance of the responders has been observed for up to 5 years.

## 5. INDICATION

BELKYRA (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of BELKYRA for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

## 6. RECOMMENDED DOSE

BELKYRA is injected into subcutaneous fat tissue in the submental area using an area-adjusted dose of 2 mg/cm<sup>2</sup>.

- A single treatment consists of up to maximum of 50 injections, 0.2 mL each (up to a total of 10 mL), spaced 1 cm apart.
- Up to 6 single treatments may be administered at intervals no less than 1 month apart. Most patients experience improvement following 2-4 treatment sessions.  
See *General Considerations for Administration (7.1) and Injection Technique (7.2)* before injection.

## **7. MODE OF ADMINISTRATION**

### **7.1 General Considerations for Administration**

Subcutaneous administration only.

BELKYRA should be administered by a healthcare professional.

Screen patients for other potential causes of submental convexity/ fullness (e.g., thyromegaly and cervical lymphadenopathy) prior to use of BELKYRA.

Give careful consideration to the use of BELKYRA in patients with excessive skin laxity, prominent platysmal bands or other conditions for which reduction of submental fat may result in an aesthetically undesirable outcome.

Use caution in patients who have had prior surgical or aesthetic treatment of the submental area. Changes in anatomy/landmarks or the presence of scar tissue may impact the ability to safely administer BELKYRA or to obtain the desired aesthetic result.

BELKYRA is clear, colorless and free of particulate matter. Visually inspect BELKYRA vials for particulate matter and/or discoloration, and discard the vial if the solution is discolored and/or contains particulate matter.

After use, discard any remaining solution in the vial.

### **7.2 Injection Technique**

The safe and effective use of BELKYRA depends on the use of the correct number and locations for injections, proper needle placement, and administration techniques.

Health care professionals administering BELKYRA must understand the relevant submental anatomy and associated neuromuscular structures in the area involved and any alterations to the anatomy due to prior surgical or aesthetic procedures [see *Warnings and Precautions (9)*].


**Avoid injections near the area of the marginal mandibular nerve [see *Warnings and Precautions (9.1)*]**

Needle placement with respect to the mandible is very important as it reduces the potential for injury to the marginal mandibular nerve, a motor branch of the facial nerve. Injury to the nerve presents as an asymmetrical smile due to paresis of lip depressor muscles [see *Warnings and Precautions (9.1)*].

To avoid injury to the marginal mandibular nerve:

- Do not inject above the inferior border of the mandible.
- Do not inject within a region defined by a 1-1.5 cm line below the inferior border (from the angle of the mandible to the mentum).
- Inject BELKYRA only within the target submental fat treatment area (see Figures 3 and 6).

**Figure 3. Avoid the Marginal Mandibular Nerve Area**




- Treatment Area
- ▨ No Injections

**Avoid injection into the platysma**

Prior to each treatment session, palpate the submental area **to ensure sufficient submental fat** and to identify subcutaneous fat between the dermis and platysma (pre-platysmal fat) within the target treatment area (Figure 4). The number of injections and the number of treatments should be tailored to the individual patient's submental fat distribution and treatment goals.



**Figure 4. Sagittal View of Platysma Area**




**Injecting into the treatment area**


Use of ice/cold packs, topical and/or injectable local anesthesia (e.g., lidocaine), oral analgesics or NSAIDS may enhance patient comfort.

Outline the planned treatment area using anatomical landmarks with a surgical pen and mark the injection sites with a 1 cm<sup>2</sup> injection grid pattern (Figures 5 and 6).

**Figure 5. Anatomical Landmarks**



**Figure 6. Treatment Area and Injection Pattern**



Do not inject BELKYRA outside the defined parameters [see *Warnings and Precautions (9.1, 9.4)*].

- Using a large bore needle, draw 1 mL of BELKYRA into a sterile 1 mL syringe and expel any air bubbles in the syringe barrel.
- Have the patient tense the platysma muscle. Pinch the submental fat and, using a 30 gauge (or smaller) 0.5 inch needle, inject 0.2 mL of BELKYRA into the pre-platysmal fat (see Figure 4) next to each of the marked injection sites by advancing the needle perpendicular to the skin.
- Injections that are too superficial (into the dermis) may result in skin ulceration. Do not withdraw the needle from the subcutaneous fat during injection as this could increase the risk of intradermal exposure and potential skin ulceration.
- Avoid injecting into the post-platysmal fat by injecting BELKYRA into fat tissue at the depth of approximately mid-way into the subcutaneous fat layer (Figure 4).
- If at any time resistance is met as the needle is inserted, indicating the possibility of contact with fascial or nonfat tissue, the needle must be withdrawn to an appropriate depth before the injection is administered.
- Avoid injecting into other tissues such as the muscle, salivary glands (including salivary ducts) and lymph nodes.
- Upon needle withdrawal, pressure may be applied to each injection site as necessary to minimize bleeding; an adhesive dressing may be applied.

## **8. CONTRAINDICATION**

BELKYRA is contraindicated in patients with the following conditions:

- presence of infection at the injection sites
- hypersensitivity to deoxycholic acid or any of the excipients

## **9. WARNING AND PRECAUTIONS**

### **9.1 Marginal mandibular nerve injury**

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported during clinical trials. To avoid the potential for nerve injury, BELKYRA should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. All marginal mandibular nerve injuries reported from the trials resolved spontaneously.

### **9.2 Dysphagia**

Difficulty swallowing (dysphagia) occurred in clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Cases of dysphagia spontaneously resolved.

Subjects with current or prior history of dysphagia were excluded from clinical trials. Avoid use of BELKYRA in these patients as current or prior history of dysphagia may exacerbate the condition.

### **9.3 Injection site hematoma/bruising**

In clinical trials, 72% of subjects treated with BELKYRA experienced injection site hematoma/bruising [see *Adverse Reactions (12)*].

BELKYRA should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

### **9.4 Injection site ulceration**

Care should be taken to avoid inadvertent intradermal or intramuscular injection. BELKYRA should be injected mid-way into the preplatysmal subcutaneous fat tissue in the submental area.

Do not withdraw the needle from the subcutaneous fat during injection, as this could increase the risk of intradermal exposure and potential skin ulceration.

#### **9.5 Risk of injecting in proximity to vulnerable anatomic structures**

To avoid potential tissue damage, BELKYRA should not be injected into or in close proximity (1-1.5 cm) to salivary glands (including salivary ducts), lymph nodes and muscles.

### **10. INTERACTIONS WITH OTHER MEDICAMENTS**

No clinical drug interaction studies have been conducted with Belkyra. Results from in vitro studies indicate that deoxycholic acid does not inhibit or induce human cytochrome P450 (CYP) enzymes at clinically relevant concentrations. Belkyra does not inhibit the following transporters: P-gp, BCRP, MRP4, MRP2, OATP1B1, OATP2B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, NTCP, and ASBT

### **11. USE IN SPECIFIC POPULATIONS**

#### **11.1 Pregnancy**

There are no adequate and well-controlled studies of BELKYRA in pregnant women. Because animal reproduction studies are not always predictive of human response, BELKYRA is not recommended for use during pregnancy.

Reproduction studies have been performed in rats and rabbits at exposures up to 1.8 times (rat) and 12 times (rabbit) the exposure at maximum recommended human dose. While they do not indicate direct or indirect harmful effects with respect to reproductive toxicity, inconclusive findings of missing intermediate lung lobe was noted in rabbits in the embryo-fetal toxicity study. The finding was significantly increased in the 30mg/kg group but was evident also at the lowest concentration 10mg/kg. This dose was associated with maternal local toxicity. The clinical significance of the finding is unclear.

#### **11.2 Lactation**

There is no information available on the presence of deoxycholic acid in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production. The

developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BELKYRA and any potential adverse effects on the breastfed child from BELKYRA or from the underlying maternal condition.

### **11.3 Pediatric Use**

Safety and effectiveness in patients below the age of 18 years have not been established and BELKYRA is not intended for use in children or adolescents.

### **11.4 Geriatric Use**

Clinical trials included limited number of subjects aged 65 and over and has not identified clinically relevant differences in responses between the elderly and younger patients. In general, treatment for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

## **12. ADVERSE REACTIONS**

### **12.1 Clinical Studies Experience**

The table below reflects the most commonly reported adverse drug reactions with BELKYRA treated subjects (n = 1207) pooled among all SMF treatment studies (Studies 03, 07, 08, 15, 16, 17, 19, 22, 23, 24, 26, 27, 28, 30, 32, and 36) compared to placebo. Subjects were evaluated in clinical studies for improvement in the appearance of submental convexity or fullness associated with submental fat. Subjects received up to 6 treatments at least 1 month apart.

**Table 2. Adverse Drug Reactions Reported by  $\geq 1\%$  of BELKYRA Treated Patients Pooled Among All SMF Treatment Studies\***

<b>Adverse reactions</b>	<b>TRADENAME (N=1207) n (%)</b>	<b>Placebo (N=948) n (%)</b>
<b>General Disorders and Administration Site Conditions</b>		
Injection site Pain	905 (75%)	297 (31.3%)
Injection site Anesthesia	704 (58.3%)	53 (5.6%)
Injection site Hematoma <sup>b</sup>	684 (56.7%)	516 (54.4%)
Injection site Edema	613 (50.8%)	218 (23.0%)
Injection site Swelling	437 (36.2%)	170 (17.9%)
Injection site Erythema	385 (31.9%)	173 (18.2%)
Injection site Induration	346 (28.7%)	35 (3.7%)
Injection site Nodule	145 (12.0%)	22 (2.3%)
Injection site Pruritus	141 (11.7%)	41 (4.3%)
Injection site Paresthesia	129 (10.7%)	26 (2.7%)
Injection site Hemorrhage	103 (8.5%)	44 (4.6%)
Injection site Discomfort	65 (5.4%)	5 (0.5%)
Injection site Bruising <sup>b</sup>	53 (4.4%)	32 (3.4%)
Injection site Warmth	29 (2.4%)	11 (1.2%)
<b>Injury, Poisoning and Procedural Complications</b>		
Nerve injury <sup>a</sup>	22 (1.8 %)	2 (0.2%)
<b>Skin and Subcutaneous Tissue Disorder</b>		
Skin tightness	34 (2.8%)	7 (0.7%)
<b>Nervous System Disorders</b>		
Headache	102 (8.5%)	63 (6.6%)

Vascular Disorders		
Hypertension	25 (2.1%)	10 (1.1%)
Gastrointestinal Disorders		
Nausea	25 (2.1%)	3 (0.3%)
Dysphagia	14 (1.2%)	2 (0.2%)

<sup>a</sup> Marginal mandibular nerve paresis

<sup>b</sup> Injection site procedure-related Adverse Events

\* Studies 03, 07, 08, 15, 16, 17, 19, 22, 23, 24, 26, 27, 28, 30, 32, and 36

### 13. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

No studies on the effects on the ability to drive and use machines have been performed.

### 14. OVERDOSE AND TREATMENT

Injection of excessive volume or decreasing the spacing between injections of BELKYRA may increase risk of adverse reactions.

### 15. STORAGE CONDITION

Store below 30°C.

The product should be discarded after the expiration date as indicated on the label.

### 16. DOSAGE FORMS AND PACKAGING AVAILABLE

BELKYRA (deoxycholic acid) injection, 10 mg/mL is a clear, colorless, sterile solution supplied in 2 mL, single patient use vials in the following dispensing pack: 4 vials

BELKYRA has a unique hologram on the vial label. If you do not see a hologram, do not use the product.

Each vial is for a single patient use. Do not dilute. Discard unused portion.

**17. NAME AND ADDRESS OF MANUFACTURER/ MARKETING AUTHORIZATION HOLDER**

Manufactured by: Hospira, Inc. McPherson, KS 67460

Imported by: Allergan (Thailand) Ltd., Bangkok, Thailand

© 2018Allergan. All rights reserved.

ALLERGAN™ and its design are trademarks of Allergan, Inc

**18. DATE OF REVISION OF PACKAGE INSERT**

Version dated: May 2018